The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Open accessPublished version of a preprint
Abstract
Abstract Purpose: Preclinical studies suggest PARP inhibition (PARPi) induces immunostimulatory micromilieu in ovarian cancer thus complementing activity of immune checkpoint blockade. We conducted a phase II trial of PARPi olaparib and anti–PD-L1 durvalumab and collected paired fresh core biopsies and blood samples to test this hypothesis. Patients and Methods: In a single-center, proof-of-concept phase II study, we enrolled women aged ≥18 with recurrent ovarian cancer. All patients were immune checkpoint inhibitor–naïve and had measurable disease per RECISTv1.1, ECOG performance status 0–2, and adequate organ and marrow function. Patients received olaparib 300 mg twice daily and durvalumab 1,500 mg intravenously every 4 weeks until disease progression, unacceptable toxicity, or withdrawal of consent. Primary endpoint was overall response rate (ORR). Secondary objectives were safety and progression-free survival (PFS). Translational objectives included biomarker evaluation for relationships with clinical response and immunomodulatory effects by treatment. Results: Thirty-five patients with ovarian cancer [median, four prior therapies (IQR, 2–5.5), predominantly platinum-resistant (86%), BRCA wild-type (77%)] received at least one full cycle of treatment. ORR was 14% [5/35; 95% confidence interval (CI), 4.8%–30.3%]. Disease control rate (PR+SD) was 71% (25/35; 95% CI, 53.7%–85.4%). Treatment enhanced IFNγ and CXCL9/CXCL10 expression, systemic IFNγ/TNFα production, and tumor-infiltrating lymphocytes, indicating an immunostimulatory environment. Increased IFNγ production was associated with improved PFS [HR, 0.37 (95% CI, 0.16–0.87), P = 0.023], while elevated VEGFR3 levels were associated with worse PFS (HR, 3.22 (95% CI, 1.23–8.40), P = 0.017]. Conclusions: The PARPi and anti–PD-L1 combination showed modest clinical activity in recurrent ovarian cancer. Our correlative study results suggest immunomodulatory effects by olaparib/durvalumab in patients and indicate that VEGF/VEGFR pathway blockade would be necessary for improved efficacy of the combination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, increased circulating levels of type I IFN- and IFNG-related cytokines as well as PD-L1 expression in malignant cells have been associated with favorable disease outcome in patients with platinum-resistant ovarian cancer receiving PARP inhibitors plus ICIs (F € arkkil € a et al., 2020; Lampert et al., 2020).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Lampert et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C. A., Oaknin, A., Dean, A. P., Colombo, N., Weberpals, J. I., Clamp, A. R., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,699
Self-citationPredictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy
Tokunaga, R., Zhang, W., Naseem, M., Puccini, A., Berger, M. D., Soni, S., McSkane, M., Baba, H., & Lenz, H.-J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.007 · Cited by 1,627
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
Self-citation
Cited by
Sorted by citations
Items 101–200 of 221
CT radiomics prediction of CXCL9 expression and survival in ovarian cancer
Gu, R. C., Tan, S., Xu, Y., Pan, D., Wang, C., Zhao, M., Wang, J., Wu, L., Zhao, S., Wang, F., et al. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01248-5 · Cited by 16
Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy
To, K. K. W., & Cho, W. C. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082166 · Cited by 16
CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer
Liu, S., Deng, P., Yu, Z., Hong, J. H., Gao, J., Huang, Y., Xiao, R., Yin, J., Zeng, X., Sun, Y.-C., et al. (2024) · Advanced Science · doi:10.1002/advs.202403782 · Cited by 13
Tang, H., Kulkarni, S., Peters, C., Eddison, J., Al-Ani, M., & Madhusudan, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087293 · Cited by 13
Khoury, R., Longobardi, G., Barnatan, T. T., Venkert, D., Alvarado, A. G., Yona, A., Buzhor, M. G., Shahar, S., Wang, Q., Acúrcio, R. C., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113812 · Cited by 15
Muaibati, M., Abasi, A., Zhang, T., Dai, Y., Li, R., Huang, F., Li, K., Tong, Q., Huang, X., & Zhuang, L. (2023) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2023.3 · Cited by 13
Recent advances in the molecular targeted drugs for prostate cancer
Gao, P., Li, T., Zhang, K., & Luo, G. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03487-3 · Cited by 13
Kim, Y., Kim, K., Joung, J., Kim, S. W., Kim, S., Lee, J.-Y., & Park, E. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1351778 · Cited by 13
Self-citationRomaniuk-Drapała, A., Skupin-Mrugalska, P., Garbuzenko, O. B., Hatefi, A., & Minko, T. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03469-0 · Cited by 11
Advanced Therapeutic Approaches for Metastatic Ovarian Cancer
Choe, S., Jeon, M., & Yoon, H. (2025) · Cancers · doi:10.3390/cancers17050788 · Cited by 11
Lee, J., Miller, A., Rose, P. G., AlHilli, M. M., Washington, C. R., John, V. S., Shah, C. A., Matsuo, K., Siedel, J., Miller, D. S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3877 · Cited by 11
Self-citationChemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?
Marques, C., da Silva, F. F., Sousa, I., & Nave, M. (2022) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003719 · Cited by 11
Rosado, M. M., & Pioli, C. (2023) · Cancers · doi:10.3390/cancers15041093 · Cited by 11
Zhou, L., Wan, Y., Zhang, L., Meng, H., Yuan, L., Zhou, S., Cheng, W., & Jiang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116733 · Cited by 10
Xiang, J., Li, J., Guo, Z., Wu, J., Ma, D., Xu, H., Shang, T., Pu, P., Cong, L., Zhou, R., et al. (2026) · Biomarker Research · doi:10.1186/s40364-026-00908-0 · Cited by 11
Jiang, H., Awuti, G., & Guo, X. (2023) · ACS Omega · doi:10.1021/acsomega.3c04856 · Cited by 10
PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review
Mehta, P., & Bothra, S. J. (2021) · Advances in genetics · doi:10.1016/bs.adgen.2021.08.002 · Cited by 10
Mutch, D. G., Voulgari, A., Chen, X., Bradley, W. H., Oaknin, A., Fidalgo, J. A. P., Montosa, F. G., Casado, A., Holloway, R. W., Powell, M. A., et al. (2024) · Cancer · doi:10.1002/cncr.35222 · Cited by 9
Gronauer, R., Madersbacher, L., Monfort‐Lanzas, P., Floriani, G., Sprung, S., Zeimet, A. G., Marth, C., Fiegl, H., & Hackl, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489235 · Cited by 8
Cheeseman, S., Levick, B., Sopwith, W., Fenton, H. M., Nam, E. J., Kim, D., Lim, S., Martin, E., Frenel, J., Bocquet, F., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1114435 · Cited by 9
Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories
Aliabadi, H. M., Manda, A., Sidgal, R., & Chung, C. (2023) · Biomolecules · doi:10.3390/biom13091306 · Cited by 9
Roads to the strategic targeting of ovarian cancer treatment
Irusta, G. (2020) · Reproduction · doi:10.1530/rep-19-0593 · Cited by 9
Jiang, G., Hong, J., Shao, F., Wen, Q., Cheng, F., Yu, T., & Zhu, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.795129 · Cited by 9
Zhang, T., Zhang, C., Fu, Z., & Gao, Q. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091768 · Cited by 8
Ethier, J.-L., Fuh, K. C., Arend, R. C., Konecny, G. E., Konstantinopoulos, P. A., Odunsi, K. O., Swisher, E. M., Kohn, E. C., & Zamarin, D. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00355 · Cited by 8
Self-citationAbulajiang, Y., Wu, Y., & He, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1658681 · Cited by 7
Pruitt, M. R., Fabian, K. P., Lee, J., & Hodge, J. W. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0438 · Cited by 8
Self-citationTraboulsi, W., Gaur, P., Kundu, S., Ramlaoui, Z., Priestley-Milianta, C., Iyengar, A. S., Shobaki, N., Sarhan, D., Lee, M.-J., Lee, J.-M., et al. (2026) · Nature Immunology · doi:10.1038/s41590-025-02383-5 · Cited by 7
Self-citationCarballo, E. V., Kim, K. H., & Penn, C. A. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.05.014 · Cited by 7
SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer
Tran, A.-Q., Sullivan, S., Chan, L. L., Yin, Y., Sun, W., Fang, Z., Dugar, S., Zhou, C., & Bae-Jump, V. L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.624498 · Cited by 7
Impact of DNA Damage Response—Targeted Therapies on the Immune Response to Tumours
Lutfi, N., Galindo-Campos, M. A., & Yélamos, J. (2021) · Cancers · doi:10.3390/cancers13236008 · Cited by 7
Bailey, M. M., Morand, S. M., Royfman, R., Lin, L., Singh, A. P., Stanbery, L., Walter, A., Hamouda, D., & Nemunaitis, J. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063173 · Cited by 7
Zhou, M., Tang, J., Huang, G., & Li, H. (2024) · Biomedicines · doi:10.3390/biomedicines12112640 · Cited by 6
Seitz, S., Dreyer, T. F., Stange, C., Steiger, K., Wohlleber, D., Anton, M., Pham, T. A., Sauter-Peschke, D., Reuning, U., Multhoff, G., et al. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101130 · Cited by 7
Zhao, Y., & Jiang, Y. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s362267 · Cited by 6
Fares, C. M., Fenerty, K. E., Chander, C., Theisen, M. K., & Konecny, G. E. (2022) · Biomarkers in Medicine · doi:10.2217/bmm-2022-0044 · Cited by 5
The Clinical Safety and Efficacy of Targeted PD-L1 Therapy with Durvalumab in Solid Tumors
Chen, M., Jiang, J. H., Chen, J., Wang, M., Lu, Y., Liu, L., Zhao, L., & Wang, L. (2023) · Current Drug Targets · doi:10.2174/1389450124666230330101651 · Cited by 6
Takahashi, N., Rajapakse, V. N., Pongor, L. S., Kumar, S., Tlemsani, C., Erwin-Cohen, R. A., Young, H. A., Hewitt, S. M., Wei, J. S., Khan, J. I., et al. (2020) · Molecular Case Studies · doi:10.1101/mcs.a005678 · Cited by 6
Luo, X., Gao, S., Sun, K., Dong, Z., & Yang, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1702121 · Cited by 6
Research progress of DNA damage repair (DDR) and DDR inhibitors in tumor immunotherapy
Liu, Q., Zhang, C., Gao, Y., Feng, D., Deng, D., & Pan, Y. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04101-9 · Cited by 7
Mercadante, M., Scheben, A., Estrada, J., Savas-Carstens, J., Sullivan, W., Housel, N., Sapar, M. L., Volpari, T., Hebner, J., Rusielewicz, T., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01251-7 · Cited by 6
Shi, J., Xiao, W., Liu, Y., Fu, X., & Peng, M. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03987-x · Cited by 5
Self-citationAdvancements in ovarian cancer immunodiagnostics and therapeutics via phage display technology
Li, Y., Li, X., Yang, K., & Tong, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1402862 · Cited by 5
A Review of the Latest Advancements in Ovarian Cancer Care Featured at ESMO 2022
Scott, B. (2023) · EMJ Oncology · doi:10.33590/emjoncol/10300067 · Cited by 5
Qureshi, M. J., Narde, G. K., Ahuja, A., Meenakshi, D. U., & Al-Balushi, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157350 · Cited by 4
Lee, C. K., Kartikasari, A. E. R., Bound, N. T., Francis, K. E., Shield‐Artin, K., Bedő, J., Nesic, K., Diamante, K., O’Connell, R. L., Madondo, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64130-6 · Cited by 4
Liu, D., Tao, K., Xu, C., Yang, W., Cai, C., Feng, C., Xiong, K., Wu, S., Lin, Y., Peng, Z., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci199035 · Cited by 5
Immunotherapy advancements in high-grade serous ovarian cancer: From promise to practice
Heidinger, M., Caruso, G., Coelho, R., Stiegeler, N., Petousis, S., Kacperczyk-Bartnik, J. P., Oseledchyk, A., Jacob, F., Kurzeder, C., Heinzelmann-Schwarz, V. A., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105312 · Cited by 4
Na, J., Liu, Y., Fang, K., Tan, Y., Liang, P., Mei, Y., Chu, J.-J., Gao, J.-M., Chen, D., & Zhang, S. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01478-4 · Cited by 4
Self-citationPorter, R. L., Bockorny, B., Corr, B. R., Mahadevan, D., Wilky, B. A., El-Khoueiry, A. B., Bullock, A. J., Hafez, N., Moser, J., Martynova, A., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013222 · Cited by 5
Song, M., Zeng, X., Wu, Q., Huang, J., Dong, J.-Y., Shao, L., Sun, Z., Lin, Y., & Chen, S. (2023) · Life · doi:10.3390/life13051183 · Cited by 4
Drug resistance biomarkers in ovarian cancer: a bibliometric study from 2017 to 2022
Cabarca, S., Ili, C., Vanegas, C., Gil, L., Vertel-Morrinson, M., & Brebi, P. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1450675 · Cited by 4
Association of nivolumab and niraparib in the management of neuroendocrine cancer of the cervix
Touhami, O., Plante, M., St-Gelais, J., & Frumovitz, M. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-004050 · Cited by 4
Wilczyński, J. R., Wilczyński, M., & Paradowska, E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1201497 · Cited by 4
Wang, Y., Qin, C. Y., Zhao, Y., Zhao, B., Li, Z., Li, T., Zhang, X., & Wang, W. (2025) · Journal of Cancer · doi:10.7150/jca.110659 · Cited by 3
Exploring the application of PD-1/PD-L1 inhibitors for ovarian cancer
Miao, X., Wang, Z., Liu, D., Ji, S., Li, J., & Zhang, S. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.101053 · Cited by 3
Rahman, A., Jalouli, M., Al-Zharani, M., & Harrath, A. H. (2026) · Biomolecules · doi:10.3390/biom16020246 · Cited by 4
Feng, Y., Han, Z., Liu, X., Yao, S., Li, Y., Han, Y., & Xia, S. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116325 · Cited by 3
Tabata, J., Huang, T., Giudice, E., Ibanez, K. R., Nair, J. R., Balaji, A., Solarz, B. B., Bolanos, V., Redd, B. A., Sato, N., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70785-6 · Cited by 3
Self-citationCurrent evidence and emerging approaches in immunotherapy for gynecological cancers
Ashonibare, V. J., Hezekiah, O. S., Kukoyi, O. S., Hassan, S. A., Afolabi, O. A., Akhigbe, T. M., & Akhigbe, R. E. (2026) · Discover Oncology · doi:10.1007/s12672-026-04785-9 · Cited by 3
Philips, T. J., Erickson, B. K., & Thomas, S. N. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1503107 · Cited by 3
Combining PARP Inhibition and Immunotherapy in BRCA-Associated Cancers
Shapiro, G. I., & Barry, S. M. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-30065-3_12 · Cited by 3
Mahadevia, H. J., Ponvilawan, B., Al‐Obaidi, A., Buckley, J. R., Subramanian, J., & Bansal, D. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241242406 · Cited by 3
Mitri, Z. I., Creason, A., Stommel, J. M., Ozmen, T. Y., Rames, M. J., Ozmen, F., Bottomly, D., Jeong, B. Y., Lim, J. Y., Sivagnanam, S., et al. (2024) · medRxiv · doi:10.1101/2024.08.29.24312245 · Cited by 3
Self-citationRohatgi, N., Rothe, M., Mangat, P. K., Garrett-Mayer, E. S., Meric‐Bernstam, F., Pisick, E. P., Alese, O. B., Reynolds, C. M., Thota, R., Vaccaro, G. M., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00279 · Cited by 10
Tomas, E. J., Davis, J., Valdés, Y. R., & Shepherd, T. G. (2026) · Cancer Biology & Therapy · doi:10.1080/15384047.2025.2611602 · Cited by 2
Jiang, R., Yu, Y., Guan, J., Ma, J., Qiu, H., Zhong, J., Liu, N., Zhao, H., Zheng, Y., & Du, Y. (2026) · Seminars in Oncology · doi:10.1016/j.seminoncol.2026.152470 · Cited by 3
Ogasawara, A., Suzuki, S., Oda, K., Yunokawa, M., Yonemori, K., Mori, M., Kurosaki, A., Mori, M., Kitano, S., Shintani, D., et al. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2026.04.007 · Cited by 2
Morgera, V., Feola, A., Romano, A., Napoli, M. V., Gabrielli, A., Avvedimento, V. E., Porcellini, A., & Pezone, A. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00779-z · Cited by 3
The DNA damage response and cancer immunotherapy
Sheng, H., & Li, G. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00958-4 · Cited by 3
Xu, D., Hu, X., Feng, Y., Lu, Z., Liu, X., Yan, H., Peng, J., Luo, S., & Yao, W. (2024) · Journal of Visualized Experiments · doi:10.3791/65841 · Cited by 2
Pereira, L. D., Wielgos-Bonvallet, M., Misirlioğlu, S., Khodadadi‐Jamayran, A., Jelinic, P., & Levine, D. A. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0515 · Cited by 2
A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
Du, T., Zhang, Z., Zhou, J., Li, S., Yao, H., Ji, M., Xu, B., & Chen, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.865085 · Cited by 2
Recent Developments in Combinatorial Immunotherapy towards Ovarian Cancer
Jain, C. K., Kulshreshtha, A., Saxena, H., Agarwal, A., & Passi, K. (2023) · Current Women s Health Reviews · doi:10.2174/1573404820666230505110617 · Cited by 2
Emerging Therapeutic Targets for Platinum-Resistant Ovarian Cancer
Wang, C. C., Gomez-Roas, M. V., & Hinchcliff, E. (2025) · Advances in Oncology · doi:10.1016/j.yao.2024.12.004 · Cited by 1
Gaillard, S. L., Verma, N., Berg, M., Harrison, J., Huang, P., Leatherman, J. M., Doucet, M., Sen, R., Suru, A., Cai, H., et al. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.01.015 · Cited by 1
Self-citationMEF2C: A Novel Transcription Factor Implicated in Human Malignant Tumors
Pan, Y., Li, J., Liu, H., Ma, J., Wang, D., Li, X., & Yuan, C. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266359306250619210412 · Cited by 1
Liu, Q., Zhang, C., Gao, Y., Feng, D., Deng, D., & Pan, Y. (2025) · Advanced Biology · doi:10.1002/adbi.202400720 · Cited by 1
Zeng, Z., Gandini, A., Bhatt, R., Proctor, M. A., Goh, N. L. L.-A., Vora, S., Walsh, T. P., Wu, S. Y., Ferguson, K., Coward, J. I. G., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03416-y · Cited by 1
Role of Immunotherapy in Ovarian Cancer: Advances, Challenges, and Future Perspectives
Garg, P., Singhal, G., Pareek, S., Khan, A., Tan, T., Wheeler, D. L., & Singhal, S. S. (2025) · Cancer treatment and research · doi:10.1007/978-3-031-97242-3_10 · Cited by 4
PARPs in tumor immunology: Signal transduction and combination therapy for the future
Jiang, L., Peng, X., Yuan, W., Qu, J., Tan, J. W., Jiao, Q., Li, Y., Peng, Y., Cao, X., & Guo, Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178298 · Cited by 1
Emerging Therapeutic Targets for Platinum-Resistant Ovarian Cancer
Wang, C. C., Gomez-Roas, M. V., & Hinchcliff, E. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2025.04.019 · Cited by 1
Genomics of ovarian cancers and the potential of precision medicine
Jarratt, A., Polidano, J., Scott, C. L., & Barker, H. E. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251396651 · Cited by 1
Azhar, M. S. M., Loh, Z., Mutamba, F. T., Algahiny, A., Yunusa, N. M., Paramasevon, S., & Almusarhed, M. (2025) · Cureus · doi:10.7759/cureus.99275 · Cited by 1
Zhang, C., Zhou, J.-B., Lei, J. H., Ang, I. L., Miao, K., Xu, X., Poon, T. C. W., Cheung, E. C. W., & Deng, C. (2026) · Protein & Cell · doi:10.1093/procel/pwaf104 · Cited by 1
Park, S. J., Bencsics, M., Veres, D. S., & Horvath, E. M. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e44789 · Cited by 1
Zhou, S., Patel, V., Kishi, N., Akhtar, K., & Tsao, C.-K. (2026) · Immunotherapy · doi:10.1080/1750743x.2026.2722581 · Cited by 2
Birrer, M. J., & Roane, B. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-77684-4.00025-8 · Cited by 1
Cioffi, R., Galli, F., Rabaiotti, E., Candiani, M., Pella, F., Candotti, G., Bocciolone, L., Marzi, P. D., Mangili, G., & Bergamini, A. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2160313 · Cited by 1
Stukan, А. I., Goryainova, А. Y., Викторович, Ш. С., Алексеевна, Г. О., Khachmamuk, Z. K., & Durov, V. V. (2022) · Tumors of female reproductive system · doi:10.17650/1994-4098-2022-18-1-54-65 · Cited by 1
Carving a niche for immunotherapy in ovarian cancer
Gupta, N., Lampert, E. J., & Lee, J. (2021) · Oncotarget · doi:10.18632/oncotarget.27864 · Cited by 1
Self-citationWu, T., Li, Y., Gong, S., Shi, R., Zhou, H., Wang, D., Zhu, K., Xue, S., Zhang, J., & Li, S. (2021) · Research Square · doi:10.21203/rs.3.rs-350037/v1
Expanding the Role of Checkpoint Inhibitors in Immune Cold Tumors
Acuña-Villaorduña, A., Gali, R., Chergui, A., & Goel, S. (2021) · Advances in Oncology · doi:10.1016/j.yao.2021.02.008
The evolving role of PARP inhibitors in advanced ovarian cancer
Levva, S., Skolariki, A., Sogka, E., Bokas, A., Assi, A., Pispirigou, M. K., & Koliou, P. (2021) · Forum of Clinical Oncology · doi:10.2478/fco-2021-0002
The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers
Bairi, K. E., Jarroudi, O. A., & Afqir, S. (2021) · Springer eBooks · doi:10.1007/978-981-16-1873-4_3
Immunological aspects of ovarian malignancy
Martins-Filho, A., Jammal, M. P., Murta, E. F. C., & Nomelini, R. S. (2022) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog4902035
Li, S., Shi, R., Zhou, H., Wang, D., Zhu, K., Xue, S., Zhang, J., Wu, T., & Li, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-350037/v2
The Role of PARP Inhibitors in the Treatment of Advanced Epithelial Ovarian Carcinoma
Kahraman, S., & Şendur, M. A. N. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_85
Yin, R., Duan, Y., Zhang, P., Zhang, T., & Zhou, L. (2023) · doi:10.2196/preprints.45835
Leveraging a necroptosis pattern to predict the prognosis and drug sensitivity of ovarian cancerPreprint
Su, N., Dou, Z., Yin, X., Xu, H., & Li, C. (2023) · Research Square · doi:10.21203/rs.3.rs-2694584/v1
Metadata
- Authors
- Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., Bagheri, M. H., Levy, E., Radke, M. R., Lipkowitz, S., Annunziata, C. M., Taube, J. M., Steinberg, S. M., & Lee, J.-M.
- Affiliations
- National Cancer Institute (US)
- 3Department of Pathology, The Johns Hopkins Medical Institution, Baltimore, Maryland.
- Duke Medical Center (US)
- University of Washington (US)
- Frederick National Laboratory for Cancer Research (US)
- 7Department of Radiology and Imaging Sciences, Clinical Center, National Cancer Institute, Bethesda, Maryland.
- National Institutes of Health (US)
- Johns Hopkins University (US)
- Corresponding author
- Lee, Jung-Min
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2020-08-14
- Volume
- 26
- Issue
- 16
- Pages
- 4268-4279
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC7442720
- OpenAlex
- W3025130660
- Cited by
- 220
- References
- 40
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 32 · 2023: 46 · 2022: 34 · 2021: 37 · 2020: 12
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NCI CCR (#ZIA BC011525)
- National Ovarian Cancer Coalition (SU2C-AACRDT16-15)
- DDCF (#2014194)
- NCI NIH (HHSN261200800001E)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- recurrent ovarian cancer, olaparib, durvalumab, PARP inhibitors, PD-L1 inhibitors, immune checkpoint blockade, combination therapy, tumor immunology, interferon-gamma, VEGFR-3, tumor-infiltrating lymphocytes, platinum-resistant ovarian cancer, BRCA wild-type, progression-free survival, biomarkers, translational biomarkers
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Progression-Free Survival, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Female, Humans, Interferon-gamma, Middle Aged, Neoplasm Recurrence, Local, Ovarian Neoplasms, Phthalazines, Piperazines, Poly(ADP-ribose) Polymerases, Gene Expression Regulation, Neoplastic, Vascular Endothelial Growth Factor A, Chemokine CXCL10, Chemokine CXCL9, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
